Drug Approval | April 17, 2026
Morepen Laboratories secures fourth consecutive USFDA ‘NIL 483’ inspection
Zero-observation outcomes strengthen global credibility and accelerate CDMO ambitions
Zero-observation outcomes strengthen global credibility and accelerate CDMO ambitions
Visit underscores push for self-reliance in essential medical consumables and India’s ambition to become a global medtech manufacturing hub
To boost compostable packaging, resin innovation, and supply chain speed
The collaboration will embed OpenAI’s advanced AI systems across Novo Nordisk’s global operations
CDSCO-cleared BSM-5700 series targets ICU, NICU, ER, OR and digital health integration under ABDM
Collaboration aims to align hospital staff learning with NABH 6th Edition standards, patient safety, and measurable quality outcomes
API-first, DPI-driven DDRS platform aims to modernize drug and medical device regulation in India
Move amid evidence of widespread reporting gaps
At the centre of this shift is Eli Lilly and Company, whose latest investments in China and Japan are helping redefine the next phase of GLP-1 supply strategy
The solution integrates key molecular cloning methods—including Golden Gate, Gibson assembly, and restriction/ligation—alongside primer design, Sanger sequencing analysis, and protein translation in a single application
Subscribe To Our Newsletter & Stay Updated
